You just read:

BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication

News provided by

BioMarin Pharmaceutical Inc.

Dec 09, 2017, 07:30 ET